BondBloxx US High Yield Healthcare Sector ETF (XHYH) is an exchange-traded fund that provides targeted exposure to high yield corporate bonds issued by companies in the healthcare sector of the US fixed income market. The fund tracks the ICE BofA Diversified High Yield US Healthcare Index, which includes below-investment grade securities from healthcare subsectors such as pharmaceuticals, biotechnology, healthcare providers, medical devices, life sciences tools, and healthcare facilities; it employs a representative sampling strategy to replicate index performance while managing liquidity and transaction costs. XHYH offers investors income generation and potential capital appreciation through a portfolio concentrated in non-investment grade debt, with typical holdings featuring issuers like pharmaceutical giants, hospital chains, biotech firms, and medical equipment manufacturers.
Launched in 2021 as part of the BondBloxx ETF suite sponsored by BondBloxx Investment Trust, a US-domiciled open-end investment company, the fund is headquartered in Rye Brook, New York, with management by Tamares Corporate Services LLC and sub-advisory by Envestnet Asset Management Ltd. Geographically, XHYH focuses exclusively on US dollar-denominated securities from domestic healthcare issuers, serving institutional and retail investors seeking sector-specific high yield strategies amid broader fixed income diversification. The ETF maintains a modified duration of approximately 3-4 years and an average yield to maturity around 7-8%, emphasizing healthcare's relative resilience in economic cycles.
In recent developments, BondBloxx expanded its ETF lineup in 2024 with additional sector-specific high yield funds, enhancing its thematic fixed income offerings; the firm also announced strategic partnerships with major wirehouses and platforms to broaden distribution. No significant acquisitions, funding rounds, or reorganizations have been reported for the sponsor in the last two years, though the broader high yield healthcare sector benefited from M&A activity among holdings, including biotech acquisitions and pharmaceutical mergers. XHYH continues to position as a niche tool for yield-hungry portfolios navigating interest rate environments and healthcare tailwinds like aging demographics and innovation pipelines.